Pr Evkeeza®
evinacumab for injection

QUEBEC

PrEVKEEZA® (evinacumab for injection) is covered by RAMQ* for eligible patients with HoFH based on the reimbursement criteria detailed below through the Quebec Institut national d'excellence en santé et en services sociaux (INESSS).

What Is EVKEEZA and How Does It Work?

EVKEEZA is the first and only ANGPTL3 inhibitor indicated as an adjunct to diet and other LDL-C lowering therapies for the treatment of adult and pediatric patients aged 6 months and older with homozygous familial hypercholesterolemia (HoFH).

The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.

Please consult the Product Monograph at https://www.ultragenyx.ca/evkeezaproductmonograph for important information relating to warnings and precautions, adverse reactions, breastfeeding, drug interactions, and dosing information.

The Product Monograph is also available by calling us at 1-833-388-5872.

The EVKEEZA Reimbursement Criteria for the Quebec INESSS Are as Follows:
(on page 114)

Conditions for Reimbursement

Recognized indication for payment:
for adjunctive treatment of individuals with homozygous familial hypercholesterolemia (HoFH):

- whose diagnosis is confirmed by genotyping or phenotyping;
  and
- whose low-density lipoprotein cholesterol (LDL-C) levels are high despite optimized treatment.

Optimized treatment means:

- in people aged 5 to 11, therapy with at least 2 lipid-lowering agents of different classes at optimal doses, unless intolerance, contraindication or ineffectiveness are present;
  or
- in people aged 12 or over, therapy with at least 3 lipid-lowering agents of different classes at optimal doses, unless intolerance, contraindication or ineffectiveness are present.

The phenotype is defined by the following 3 elements:

- LDL-C levels >10 mmol/L before starting treatment;
- the presence of xanthomas before the age of 10;
- the presence in both parents of confirmed heterozygous familial hypercholesterolemia.

Initial request is allowed for up to 4 months.

Upon subsequent requests, the physician must provide the data to demonstrate the beneficial effects of the treatment, i.e., a reduction of at least 20% of LDL-C levels from the values before the start of treatment with evinacumab. Subsequent requests are allowed for up to 12 months.

Authorizations are given at a maximum dose of 15 mg/kg every 4 weeks.

For more information on applying for EVKEEZA® coverage, we can arrange an appointment at your convenience, or you can go to the UltraCare website. You can also find the UltraCare Enrolment Form on the UltraCare website.

*Official Mark of the Régie de l'assurance maladie du Québec.